110414 ⎘
Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV concerning HIV env New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
COMPOSITIONS COMPRISING HIV-1 ENVELOPES WITH ENGINEERED V1V2 FOR BROAD V3-GLYCAN NEUTRALIZING ANTIBODY BINDING
#2CH505 ENVELOPES TO ENGAGE AND MATURE CD4 BINDING SITE NEUTRALIZING ANTIBODIES
#3HIV Immunogens, Vaccines, and Methods Related Thereto
#4IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS
#5CH505 ENVELOPES TO ENGAGE AND MATURE CD4 BINDING SITE NEUTRALIZING ANTIBODIES
#6COMPOSITIONS COMPRISING V2 OPT HIV ENVELOPES
#7COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#8METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
#9GLYCOSYLATION ENGINEERING
#10IMMUNOGENS AND VACCINE COMPOSITIONS AGAINST HIV
#11BASE-COVERED HIV-1 ENVELOPE ECTODOMAINS AND THEIR USE
#12EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION
#13COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
#14SYSTEMS OF SINGLE-CELL LABELING AND METHODS OF USING THE SAME
#15HIV-1 ENVELOPE STABILIZING MUTATIONS
#16COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION
#17ANTIBODIES TARGETING HIV ESCAPE MUTANTS
#18RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES
#19GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE
#20IMMUNOGENIC TRIMERS
#21COMPOSITIONS AND METHODS FOR MULTIVALENT SURFACE DISPLAY ON ENVELOPED PARTICLES
#22HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION
#23Conformationally Specific Viral Immunogens
#24COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#25METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
#26MEASLES-HIV OR MEASLES-HTLV VACCINE
#27COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
#28MODIFIED ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS AND USE THEREOF
#29COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#30Trimer Stabilizing HIV Envelope Protein Mutations
#31Epitope focusing by variable effective antigen surface concentration
#32Recombinant HIV-1 envelope proteins and their use
#33Compositions comprising modified HIV envelopes
#34Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
#35ENGINEERED BACTERIOPHAGE T4 NANOPARTICLES AS A POTENTIAL TARGETED ACTIVATOR OF HIV-1 LATENCY IN CD4+ HUMAN T-CELLS
#36IMMUNOGENIC TRIMERS
#37Trimer stabilizing HIV envelope protein mutations
#38COMPOSITIONS AND METHODS FOR DETECTING HIV LATENCY, TREATING HIV INFECTION, AND REVERSING HIV LATENCY
#39HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants
#40Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#41Chimeric molecules and uses thereof
#42Compositions and methods for identifying and sorting antigen-specific B cells
#43USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
#44HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations
#45Antigen Delivery Vectors and Constructs
#46COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#47HIV-1 envelope stabilizing mutations
#48Virtual assistant focused user interfaces
#49Conformationally-specific viral immunogens
#50INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS
#51Compositions comprising HIV envelopes to induce CH235 lineage antibodies
#52Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
#53Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
#54Trimer stabilizing HIV envelope protein mutations
#55Compositions and methods for inducing HIV-1 antibodies
#56HIV vaccine formulation
#57NOVEL MAMMALIAN EXPRESSED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN ANTIGENS
#58Epitope restriction for antibody selection
#59Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein
#60Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#61Epitope focusing by variable effective antigen surface concentration
#62Scaffolded HIV-1 Env GP140 trimer immunogen
#63Antiviral vaccines with improved cellular immunogenicity
#64Trimer stabilizing HIV envelope protein mutations
#65HIV envelope glycoprotein immunogens
#66Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
#67Biochemically stabilized HIV-1 Env trimer vaccine
#68Synthetic conjugate of CpG DNA and T-help/CTL peptide
#69ENGINEERED VARIANTS OF HIV-1 ENV FOR PRESENTATION OF QUARTENARY EPITOPES
#70Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
#71Compositions and methods for identifying and sorting antigen-specific B cells
#72Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
#73Multivalent glycopeptides that tightly bind to target proteins
#74Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#75Compositions and methods for inducing HIV-1 antibodies
#76Directed evolution of multivalent glycopeptides that tightly bind to target proteins
#77Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#78Recombinant HIV compositions and uses thereof in animal models
#79Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits
#80Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
#81Chimeric molecules and uses thereof
#82Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
#83Biochemically stabilized HIV-1 Env trimer vaccine
#84Compositions comprising HIV envelopes to induce CH235 lineage antibodies
#85Recombinant HIV-1 envelope proteins and their use
#86Epitope focusing by variable effective antigen surface concentration
#87Polypeptides targeting HIV fusion
#88Genome editing reagents and their use
#89Helix-grafted proteins as inhibitors of disease-relevant protein-protein interactions
#90Method for detecting HIV-1 co-receptor tropism
#91Production of soluble HIV envelope trimers in planta
#92Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens
#93Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
#94Virus-like particles with high-density coating for inducing the expression of antibodies
#95Antiviral vaccines with improved cellular immunogenicity
#96Recombinant HIV epitopes and uses thereof
#97Stable Production of Lentiviral Vectors
#98Biochemically stabilized HIV-1 env trimer vaccine
#99Method for detecting HIV-1-specific antibodies using clade C env polypeptides
#100Transgenic VERO-CD4/CCR5 cell line
#101HIV vaccine formulation
#102Engineered outer domain (EOD) of HIV GP120 and mutants thereof
#103Nucleic acids encoding mosaic conserved region HIV immunogenic polypeptides
#104INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS
#105N-glycan deleted HIV-1 envelope glycoprotein trimers
#106HIV-1 vaccine
#107Scaffolded HIV-1 vaccine immunogens
#108HIV peptide vaults and methods of making and using thereof
#109Conformationally Specific Viral Immunogens
#110Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120
#111Immunogenic trimers
#112Recombinant HIV-1 envelope proteins and their use
#113Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
#114Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same
#115Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising gag, pol, vif and nef epitopes
#116HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
#117Trimer stabilizing HIV envelope protein mutations
#118Therapeutic peptides and vaccines
#119Antibody evolution immunogens
#120Dps fusion proteins for use in vaccines and diagnostics
#121ANTI-HLA ASSAY AND METHODS
#122Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use
#123Consensus/ancestral immunogens
#124Synthetic conjugate of CpG DNA and T-help/CTL peptide
#125HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants
#126Epitope focusing by variable effective antigen surface concentration
#127Biochemically stabilized HIV-1 Env trimer vaccine
#128Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#129Method of inducing an immune response against human immunodeficiency virus comprising administering immunogenic compositions comprising authentic trimeric HIV-1 envelope glycoproteins containing a long linker and tag
#130Engineered outer domain (eOD) of HIV GP120, mutants and use thereof
#131EFFICIENT PRODUCTION OF PEPTIDES
#132Immunogens for HIV vaccination
#133Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
#134Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
#135Conformationally specific viral immunogens
#136Polypeptides targeting HIV fusion
#137Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
#138Trimer stabilizing HIV envelope protein mutations
#139Immunogenic polypeptides
#140Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
#141Compositions for preventing and/or treating an infection by an HIV-1 virus
#142Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides
#143V1/V2 fragments of a HIV-1 envelope glycoprotein
#144DOUBLE ENGINEERED HIV-1 ENVELOPES
#145Stable production of lentiviral vectors
#146HIV vaccine formulation
#147Biochemically stabilized HIV-1 Env trimer vaccine
#148Stable immunogen based on inner domain of HIV-1 gp120 for inducing immunity against HIV
#149Transgenic Vero-CD4/CCR5 cell line
#150Antiviral vaccines with improved cellular immunogenicity
#151Recombinant HIV-1 envelope proteins and their use
#152Inhibitors of HIV-1 entry and methods of use thereof
#153PEPTIDES MIMICKING HIV-1 VIRAL EPITOPES IN THE V2 LOOP FOR THE GP120 SURFACE ENVELOPE GLYCOPROTEIN
#154Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
#155Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
#156Replication-competent VSV-HIV Env vaccines
#157Viral inhibitory nucleotide sequences and vaccines
#158Influenza antigen delivery vectors and constructs
#159Soluble HIV-1 envelope glycoprotein trimers
#160Materials and methods for producing cleaved, HIV-1 envelope glycoprotein trimers
#161MPER-liposome conjugates and uses thereof
#162Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
#163Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes
#164Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
#165Vaccine and therapeutic delivery system
#166HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies
#167Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
#168Directed evolution of multivalent glycopeptides that tightly bind to target proteins
#169Multivalent glycopeptides that tightly bind to target proteins
#170Soluble HIV-1 envelope glycoprotein trimers
#171Soluble HIV-1 envelope glycoprotein trimers
#172Approach to produce HIV-1 GP140 envelope protein trimers
#173Approach to produce HIV-1 GP140 envelope protein trimers
#174Method of purifying authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
#175Authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
#176Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
#177HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereof
#178Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
#179Recombinant protein bodies as immunogen-specific adjuvants
#180Compositions and methods comprising hydrocarbon-stapled polypeptides
#181Mosaic HIV envelope immunogenic polypeptides
#182Methods to improve vector expression and genetic stability
#183HIV-1 vaccine
#184Designing a soluble full-length HIV-1 gp41 trimer
#185Engineered outer domain (eOD) of HIV gp120 and mutants thereof
#186COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
#187Stabilized HIV-1 peptide constructs comprising the gp120 C5 domain and gp41 hydrophilic domain
#188Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverage
#189Dps fusion proteins for use in vaccines and diagnostics
#190Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins
#191Expression of HIV inhibitors by Mesenchymal stem cells
#192Vaccine and therapeutic delivery system
#193Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#194Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
#195RECOMBINANT PRODUCTION OF HIV-1 ENVELOPE GLYCOPROTEINS
#196Compositions for preventing and/or treating an infection by an HIV-1 virus
#197Antiviral vaccines with improved cellular immunogenicity
#198Solid support comprising HIV-1 clade C envelope peptides for the detection of HIV-1-specific antibodies
#199HIV Antigens and Antibodies
#200Synthetic conjugate of CpG DNA and T-help/CTL peptide
#201Antibody evolution immunogens
#202Stabilized trimeric HIV-1 GP41 fusion inhibitor polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif
#203SYNTHETIC ENV PROTEINS
#204Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens
#205HIV-1 GP 120 V1/V2 antigens and immunological uses thereof
#206Cell penetrating peptides
#207Methods for identifying HIV neutralizing antibodies
#208Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
#209STABILIZED GP120
#210Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domain
#211FRET-based reagents and methods for identifying anti-HIV compounds
#212Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine
#213Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
#214Antigen delivery vectors and constructs
#215Epitope focusing by variable effective antigen surface concentration
#216Immunogenic compositions comprising FIV and HIV gag antigens
#217STABLE PEPTIDE MIMETICS OF THE HIV-1 GP41 PRE-HAIRPIN INTERMEDIATE
#218Immunogens for HIV vaccination
#219COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS
#220Efficient production of peptides
#221Compositions and methods for generating an immune response
#222HIV consensus envelope sequences and methods for using the same
#223Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
#224Method of making biologically active alpha-beta peptides
#225HIV-1 gp120 mini V3 loop and uses thereof
#226Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
#227Synthetic viruses and uses thereof
#228Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
#229Influenza antigen delivery vectors and constructs
#230Truncated HIV envelope proteins (ENV), methods and compositions related thereto
#231HIV-1 south african subtype C env proteins
#232HIV-1 envelope glycoprotein
#233hTERT sequences and methods for using the same
#234Designing a soluble full-length HIV-1 gp41 trimer
#235Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41
#236Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction
#237Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
#238Stable production of lentiviral vectors
#239Serpin-finger fusion polypeptide
#240Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
#241Methods for identifying broadly neutralizing antibodies utilizing recombinant HIV-1 envelope glycoproteins comprising stabilizing mutations
#242Rapid selection method for HIV gp-120 variants
#243Compositions for detecting an infection by an HIV-1 virus
#244HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies
#245Method for ameliorating pain by modification of NMDA receptors through inhibition of SRC
#246Methods to improve vector expression and genetic stability
#247Reovirus vaccines and methods of use therefor
#248Method of making biologically active alpha-beta peptides
#249DPS fusion proteins for use in vaccines and diagnostics
#250Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
#251Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
#252B-cell stimulating fusion proteins of an antigen with BAFF or APRIL
#253Vaccine for enveloped viruses
#254Vaccine and therapeutic delivery system
#255Peptides mimicking HIV-1 viral epitopes in the V2 loop for the GP120 surface envelope glycoprotein
#256Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#257HIV-1 latency model for high throughput screening
#258HIV consensus envelope sequences and methods for using the same
#259EPITOPE TESTING USING SOLUBLE HLA
#260ANTI-HLA ASSAY AND METHODS
#261Conformationally stabilized HIV envelope immunogens
#262NANOHAIR STRUCTURE AND AN APPLICATION THEREFOR
#263Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation
#264Antigen delivery vectors and constructs
#265Immunological Compositions for HIV
#266METHOD OF USING ADENOVIRAL VECTORS TO INDUCE AN IMMUNE RESPONSE
#267COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS
#268COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS
#269Reassortant influenza B viruses
#270Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
#271MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION
#272Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics
#273Viral chemokine-antigen fusion proteins
#274EXPRESSION CASSETTES ENDCODING HIV-1 SOUTH AFRICAN SUBTYPE C MODIFIED PROTEINS
#275EXPRESSION OF HIV POLYPEPTIDES AND PRODUCTION OF VIRUS-LIKE PARTICLES
#276Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
#277Albumin-Fused Anti-Angiogenesis Peptides
#278Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain
#279Targeted particles and methods of using the same
#280Composition and Method for Mediating an Immune Response
#281NUCLEIC ACID SEQUENCES ENCODING EXPANDABLE HIV MOSAIC PROTEINS
#282HIV-1 clade a consensus sequences, antigens, and transgenes
#283Chimeric HIV fusion proteins as vaccines
#284Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
#285HIV vaccine formulations
#286Method of inducing neutralizing antibodies to human immunodeficiency virus
#287MIMOTOPES OF HIV ENV
#288ALPHABODIES FOR HIV ENTRY INHIBITION
#289Chimeric protein, method for manufacturing the same, nano-sensor in which the chimeric protein is fixed, and application thereof
#290MIMOTOPES OF HIV AND USES THEREOF
#291Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region
#292SOLUBLE IGF RECEPTORS AS ANTI-ANGIOGENIC AGENTS
#293Viral infection enhancing peptide
#294Expression in plants of HIV-related proteins
#295HIV CD4 BINDING SITE BASED COVALENT IMMUNOGEN COMPOSITIONS
#296Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens
#297Subgenomic replicons of the flavivirus dengue
#298Simian Adenovirus Vectors and Methods of Use
#299Methods and compositions for inhibiting viral entry into cells
#300Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use